(Q39701114)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20495920%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

title

In vitro sequence-dependent synergism between paclitaxel and gefitinib in human lung cancer cell lines (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20495920%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

1 reference

1 reference

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20495920%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Yi-Long Wu

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20495920%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

author name string

Hua Cheng

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20495920%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

She-Juan An

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20495920%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Xu-Chao Zhang

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20495920%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Song Dong

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20495920%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Yi-Fang Zhang

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20495920%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Zhi-Hong Chen

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20495920%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Hua-Jun Chen

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20495920%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Qiu-Xiong Lin

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20495920%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

publication date

22 May 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20495920%20AND%20SRC:MED&resulttype=core&format=json

Cancer Chemotherapy and Pharmacology

3 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20495920%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

volume

67

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20495920%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20495920%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

page(s)

637-646

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20495920%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00280-010-1347-4

3 February 2020

exact match

0 references

cites work

Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1347-4

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1347-4

Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1347-4

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1347-4

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1347-4

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1347-4

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1347-4

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1347-4

Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1347-4

Promotion of microtubule assembly in vitro by taxol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1347-4

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1347-4

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1347-4

Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1347-4

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1347-4

Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1347-4

Properties of mitotic cells prepared by mechanically shaking monolayer cultures of Chinese hamster cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1347-4

Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1347-4

Stuck in division or passing through: what happens when cells cannot satisfy the spindle assembly checkpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1347-4

How do anti-mitotic drugs kill cancer cells?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1347-4

Mitotic checkpoint slippage in humans occurs via cyclin B destruction in the presence of an active checkpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1347-4

Chemical induction of mitotic checkpoint override in mammalian cells results in aneuploidy following a transient tetraploid state.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1347-4

Evidence that mitotic exit is a better cancer therapeutic target than spindle assembly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1347-4

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1347-4

Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1347-4

Molecular mechanisms of ZD1839-induced G1-cell cycle arrest and apoptosis in human lung adenocarcinoma A549 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1347-4

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1347-4

Integration of novel therapeutics into combined modality therapy of locally advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1347-4

Epidermal growth factor receptor tyrosine kinase inhibitors plus chemotherapy: case closed or is the jury still out?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1347-4

Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1347-4

Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1347-4

Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1347-4

Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1347-4

Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1347-4

ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of non-small-cell lung cancer (NSCLC)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-010-1347-4

10.1007/S00280-010-1347-4

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20495920%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

1 reference